ONESOURCE SPECIALTY PHARMA LTD
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clini… Read more
ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) - Total Assets
Latest total assets as of September 2025: ₹80.13 Billion INR
Based on the latest financial reports, ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) holds total assets worth ₹80.13 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ONESOURCE SPECIALTY PHARMA LTD - Total Assets Trend (2023–2025)
This chart illustrates how ONESOURCE SPECIALTY PHARMA LTD’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ONESOURCE SPECIALTY PHARMA LTD - Asset Composition Analysis
Current Asset Composition (March 2025)
ONESOURCE SPECIALTY PHARMA LTD's total assets of ₹80.13 Billion consist of 14.4% current assets and 85.6% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 2.1% |
| Accounts Receivable | ₹4.48 Billion | 5.9% |
| Inventory | ₹1.58 Billion | 2.1% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹181.28 Million | 0.2% |
| Goodwill | ₹447.46 Million | 0.6% |
Asset Composition Trend (2023–2025)
This chart illustrates how ONESOURCE SPECIALTY PHARMA LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ONESOURCE SPECIALTY PHARMA LTD's current assets represent 14.4% of total assets in 2025, an increase from 11.4% in 2023.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2025, up from 0.3% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 16.0% in 2023.
- Asset Diversification: The largest asset category is accounts receivable at 5.9% of total assets.
ONESOURCE SPECIALTY PHARMA LTD Competitors by Total Assets
Key competitors of ONESOURCE SPECIALTY PHARMA LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ONESOURCE SPECIALTY PHARMA LTD - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ONESOURCE SPECIALTY PHARMA LTD generates 0.19x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ONESOURCE SPECIALTY PHARMA LTD is currently not profitable relative to its asset base.
ONESOURCE SPECIALTY PHARMA LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 0.98 | - |
| Quick Ratio | 0.77 | 0.83 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | ₹236.95 Million | ₹ -273.82 Million | - |
ONESOURCE SPECIALTY PHARMA LTD - Advanced Valuation Insights
This section examines the relationship between ONESOURCE SPECIALTY PHARMA LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.85 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 477.0% |
| Total Assets | ₹75.50 Billion |
| Market Capitalization | $1.20 Billion USD |
Valuation Analysis
Below Book Valuation: The market values ONESOURCE SPECIALTY PHARMA LTD's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ONESOURCE SPECIALTY PHARMA LTD's assets grew by 477.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ONESOURCE SPECIALTY PHARMA LTD (2023–2025)
The table below shows the annual total assets of ONESOURCE SPECIALTY PHARMA LTD from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹75.50 Billion | +476.97% |
| 2024-03-31 | ₹13.09 Billion | -34.86% |
| 2023-03-31 | ₹20.09 Billion | -- |